1. Home
  2. RVMD vs SYF Comparison

RVMD vs SYF Comparison

Compare RVMD & SYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolution Medicines Inc.

RVMD

Revolution Medicines Inc.

HOLD

Current Price

$140.70

Market Cap

19.2B

Sector

Health Care

ML Signal

HOLD

SYF

Synchrony Financial

HOLD

Current Price

$75.17

Market Cap

25.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVMD
SYF
Founded
2014
1932
Country
United States
United States
Employees
883
20000
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
19.2B
25.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RVMD
SYF
Price
$140.70
$75.17
Analyst Decision
Strong Buy
Buy
Analyst Count
19
19
Target Price
$140.84
$84.83
AVG Volume (30 Days)
3.8M
3.4M
Earning Date
05-07-2026
04-21-2026
Dividend Yield
N/A
1.57%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$84.92
Revenue Next Year
$533.02
$5.11
P/E Ratio
N/A
$7.85
Revenue Growth
N/A
N/A
52 Week Low
$34.00
$51.72
52 Week High
$155.70
$88.77

Technical Indicators

Market Signals
Indicator
RVMD
SYF
Relative Strength Index (RSI) 62.82 56.06
Support Level $93.39 $74.95
Resistance Level $155.70 $75.21
Average True Range (ATR) 7.53 1.95
MACD -0.07 -0.09
Stochastic Oscillator 75.43 42.55

Price Performance

Historical Comparison
RVMD
SYF

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

About SYF Synchrony Financial

Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).

Share on Social Networks: